Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability Study of V501 in Japanese Boys (V501-200)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese male~* Have a legal representative who provides written informed consent for the trial on the participant's behalf~* Have a legal representative who is able to read, understand, and complete the vaccine report card~* Has not yet had coitarche and does not plan on becoming sexually active from Day 1 through Month 7 of the study~* Other inclusion criteria will be discussed with the investigator during screening~Exclusion Criteria:~* Currently enrolled in clinical studies of investigational agents~* History of known prior vaccination with an HPV vaccine or plans to receive one outside the study~* History of severe allergic reaction that required medical intervention~* Allergic to any vaccine component, including aluminum, yeast, or BENZONASE™~* Received immune globulin or blood-derived products in the past 6 months or plans to receive any before Month 7 of the study~* History of splenectomy, is currently immunocompromised, or has been diagnosed with immunodeficiency, Human Immunodeficiency Virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition~* Received immunosuppressive therapy in the past year, excluding inhaled, nasal, or topical corticosteroids~* Known thrombocytopenia or coagulation disorder that would contraindicate intramuscular injections~* Ongoing alcohol or drug abuse within the past 12 months~* History of genital warts or a positive test for HPV

- Gender: MALE
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- V501 (Type: EXPERIMENTAL): 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6

Based on this trial design, predict the completion outcome and termination type (if applicable).